Patents by Inventor Adam James Davenport

Adam James Davenport has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10174016
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 8, 2019
    Assignee: BEYER AKTIENGESELLSCHAFT
    Inventors: Adam James Davenport, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho, Jürgen Klar
  • Publication number: 20180093980
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 21, 2017
    Publication date: April 5, 2018
    Inventors: Adam James DAVENPORT, Nico Bräuer, Oliver Martin Fischer, Andrea Rotgeri, Antje Rottmann, Ioana Neagoe, Jens Nagel, Anne-Marie Godinho-Coelho
  • Publication number: 20180072713
    Abstract: The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 15, 2018
    Inventors: Adam James DAVENPORT, Nico BRÄUER, Oliver Martin FISCHER, Andrea ROTGERI, Antje ROTTMANN, Ioana NEAGOE, Jens NAGEL, Anne-Marie GODINHO-COELHO
  • Patent number: 8912176
    Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: December 16, 2014
    Assignee: Evotec AG
    Inventors: Adam James Davenport, David James Hallett, Christopher Charles Stimson
  • Patent number: 8691804
    Abstract: The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. These compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: April 8, 2014
    Assignee: Evotec AG
    Inventors: Adam James Davenport, David James Hallett, Massimo Corsi
  • Patent number: 8349831
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: January 8, 2013
    Assignee: Amgen Inc.
    Inventors: Thomas S. Coulter, Adam James Davenport, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael Gerard Kelly, Steve Fong Poon, Andrew Tasker, Ning Xi, Qing Ping Zeng
  • Publication number: 20120040952
    Abstract: The invention relates to compounds of formula (I), wherein R, R1, m, n and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
    Type: Application
    Filed: January 29, 2010
    Publication date: February 16, 2012
    Applicant: EVOTEC AG
    Inventors: Adam James Davenport, David James Hallett, Christopher Charles Stimson
  • Publication number: 20110105459
    Abstract: The invention relates to compounds of formula (I) wherein R, R0, R1, m, n and X1 to X4 have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
    Type: Application
    Filed: May 5, 2009
    Publication date: May 5, 2011
    Applicant: EVOTEC AG
    Inventors: Adam James Davenport, David James Hallett, Massimo Corsi
  • Publication number: 20110046130
    Abstract: The invention relates to compounds of formula (I), wherein X1a, X1 to X5, Ra, Rb, n and R have the meaning as cited in the description and the claims. Said compounds are useful as Histamine H3 receptor antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
    Type: Application
    Filed: March 27, 2009
    Publication date: February 24, 2011
    Applicant: Evotec AG
    Inventors: Adam James Davenport, David James Hallett, Frédéric Marlin, Mark Gemkow
  • Publication number: 20100234377
    Abstract: The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever, pain including allodynia and nociception, eating disorders, cachexia, brain injuries, cancer of the genitals, sleep apnea, cardiovascular disease, flush effect associated with nicotinic acid and related compounds or for the promotion of wound healing. Certain compounds of general formula (I) are new and the invention also relates to these compounds and to their use in medicine.
    Type: Application
    Filed: April 7, 2008
    Publication date: September 16, 2010
    Applicant: Evotec AG
    Inventors: Babette Aicher, Arndt-Rene Kelter, Thomas Stephen Coulter, Steven Taylor, Adams James Davenport, Thomas Hesterkamp, Christian Kirchhoff
  • Publication number: 20080221101
    Abstract: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2007
    Publication date: September 11, 2008
    Applicant: Amgen Inc.
    Inventors: Thomas S. Coulter, Adam James Davenport, Christopher H. Fotsch, Chiara Ghiron, Paul E. Harrington, Michael Gerard Kelly, Steve Fong Poon, Andrew Tasker, Ning Xi, Qing Ping Zeng